|Thomas Olin was born in 1958 and is the CEO. Ph.D. in physiology and M.Sc. in biology, chemistry and geosciences. Olin has 20 years' experience of both scientific and business management from biotechnology and pharmaceutical companies. He was part of the management group that led the hiving off of Biovitrum from Pharmacia and was later part of the research and business development management at Biovitrum. Olin was responsible for the hiving off of iNovacia from Biovitrum in 2006 and has been CEO at iNovacia since 2006. He also has extensive experience of the licensing of pharmaceutical development projects.
Shareholding: 906,300 shares.
|Martin Norin was born in 1959. CSO and member of the Board of iNovacia AB since 2006. Ph.D. in biochemistry and M.Sc. in chemistry from the KTH Royal Institute of Technology in Stockholm. Norin has long experience of working in pharmaceutical research. Among other things, he has been a project manager and member of the committee for pharmaceutical development in the preclinical phase at Pharmacia and Biovitrum. Along with Thomas Olin, he led the spin-off of iNovacia from Biovitrum in 2006. As the person in charge of chemistry at Biovitrum AB, Norin was responsible for more than 70 scientists.
Shareholding: 13,400 shares and 40,000 options.
|Markus Thor was born in 1971. CBO at iNovacia AB since 2009.
M.Sc. from Umeå University, specializing in organic chemistry and MBA from Stockholm School of Economics. Thor has long experience of international transactions and business development in the pharmaceutical industry. For three years, he was Vice President of Corporate Development at Biovitrum AB, and was previously Director of Business Development in the same company. During his 16 years in Pharmacia, Biovitrum and iNovacia, Thor has worked around 8 years in R&D and around 8 years in business development.
Shareholding: 40,000 shares and 40,000 options.
|Lars Ährlund-Richter was born in 1952. CSO at Kancera since 2010. Professor of molecular embryology, lecturer and Ph.D. in tumor immunology at the Karolinska Institute in Stockholm and M.Sc. in chemistry and biology at Stockholm University. Postdoctoral Fellow during 1987-88 the National Institute of Medical Research in London. Lars is research group leader at the Dept of Women's and Children's Health, Karolinska Institute in Solna. He has long experience of experimental cancer research, human embryology including cell and developmental biology.
Shareholding: 4,000 shares and 30,000 options.